Testosterone Cypionate Cancer Risk Signal Review

What the Evidence Actually Shows About Testosterone and Cancer

Decades of biological theory held that testosterone fueled prostate cancer growth, a view derived largely from Charles Huggins' 1941 castration experiments. That framing shaped clinical practice for 60 years. More recent randomized data, including the T-Trials published in the New England Journal of Medicine in 2016 (N=788 men aged 65 or older with confirmed hypogonadism), found no statistically significant difference in prostate cancer incidence between testosterone-treated and placebo groups over 12 months of follow-up (Snyder et al., NEJM 2016).

That null finding does not end the conversation. Short follow-up, selected enrollment, and PSA surveillance differences all limit generalizability. The signal that does emerge consistently is PSA elevation, not confirmed malignancy.

The PSA Signal in T-Trials

In the T-Trials sexual-function trial, mean PSA increased by 0.30 ng/mL in the testosterone arm versus 0.07 ng/mL in the placebo arm (P<0.001) (Snyder et al., NEJM 2016). That difference is modest in absolute terms. Still, any PSA rise mandates clinical interpretation, particularly in men with baseline PSA between 2.5 and 4.0 ng/mL where biopsy thresholds are already under discussion with urology.

The Saturation Model and Its Practical Meaning

Abraham Morgentaler's prostate saturation model, supported by tissue androgen receptor data, proposes that prostate androgen receptors reach saturation at serum testosterone concentrations near 250 ng/dL (Morgentaler and Traish, Eur Urol 2009). Above that threshold, incremental increases in serum testosterone produce diminishing additional androgen receptor activation in prostate tissue. This model helps explain why restoring a hypogonadal man from 150 ng/dL to 500 ng/dL may not substantially increase prostate cancer risk beyond what exists at mid-normal levels. The model does not apply to supraphysiologic testosterone concentrations used illicitly in bodybuilding contexts, which may overwhelm receptor saturation.

TRAVERSE: The Largest Safety Dataset

The TRAVERSE trial enrolled 5,204 men with hypogonadism and pre-existing cardiovascular disease or high cardiovascular risk (Lincoff et al., NEJM 2023). Prostate cancer event rates were 0.19 per 100 person-years in the testosterone arm versus 0.18 per 100 person-years in placebo. That difference did not reach statistical significance. Urinary retention and prostate biopsy rates were modestly higher in the testosterone arm, which reflects expected PSA-driven clinical activity rather than confirmed carcinogenesis.

Prostate Cancer: Absolute Contraindications and High-Risk Groups

Active or suspected prostate cancer is an absolute contraindication to testosterone cypionate under both the Endocrine Society 2018 Clinical Practice Guideline and the American Urological Association 2022 guidelines. This is not a relative risk-benefit judgment; it is a firm clinical boundary.

Men With Prior Prostate Cancer

The question of TRT in men with treated, low-risk prostate cancer is evolving. Several retrospective series and small prospective studies report no acceleration of biochemical recurrence in carefully selected men on active surveillance or after radical prostatectomy with undetectable PSA. Khera et al. Published a prospective study of 103 men receiving testosterone therapy after radical prostatectomy; biochemical recurrence rates did not exceed those in untreated controls (Khera et al., J Urol 2009). These data remain insufficient for a blanket recommendation. Any testosterone use in this population requires shared decision-making with urology and PSA monitoring every 3 to 6 months.

PSA Velocity as an Actionable Threshold

The Endocrine Society guideline specifies that testosterone therapy should be stopped and urology referral initiated if PSA rises by more than 1.4 ng/mL in any 12-month period on therapy, or if PSA exceeds 4.0 ng/mL (Bhasin et al., J Clin Endocrinol Metab 2018). A rise above those thresholds does not confirm cancer; it triggers structured diagnostic evaluation.

Rectal Examination Findings

Digital rectal examination (DRE) should be performed at baseline and at 12 months. A newly palpable nodule or induration at any follow-up visit overrides PSA trajectory and mandates immediate urology referral regardless of PSA value.

Breast Cancer Risk in Men on Testosterone Cypionate

Male breast cancer accounts for approximately 1% of all breast cancer diagnoses in the United States, with an estimated 2,800 new cases per year according to the American Cancer Society. The relationship between exogenous testosterone and male breast cancer is biologically plausible through aromatase conversion to estradiol, but direct epidemiologic evidence linking TRT to male breast cancer incidence is absent from the randomized literature.

Estradiol Elevation on TRT

Testosterone cypionate at standard hypogonadism doses (100 to 200 mg intramuscularly every 1 to 2 weeks) raises serum estradiol through peripheral aromatization (Ramasamy et al., BJU Int 2014). Elevated estradiol in men correlates with gynecomastia and, theoretically, with ER-positive breast tissue stimulation. No randomized controlled trial has quantified a breast cancer incidence difference attributable to TRT in men.

Absolute Contraindication

Known or suspected male breast cancer is an absolute contraindication to testosterone cypionate per the FDA-approved prescribing label (FDA label, testosterone cypionate injection). Baseline breast examination is standard of care; any palpable mass before or during therapy warrants imaging and biopsy evaluation before continuing treatment.

Erythrocytosis: The Most Consistently Observed Risk Signal

Polycythemia is the most frequently documented adverse laboratory finding on testosterone replacement therapy. Testosterone stimulates erythropoietin production and direct erythroid progenitor proliferation in bone marrow (Coviello et al., J Clin Endocrinol Metab 2008). This is not a cancer risk per se, but elevated hematocrit increases blood viscosity and thrombotic risk, which intersects with oncology through thromboembolic events.

Incidence Rates

A 2023 meta-analysis of 35 randomized trials (N=5,368 men) found that testosterone therapy increased the odds of erythrocytosis (hematocrit >50% or hemoglobin >17 g/dL) by an odds ratio of 3.69 (95% CI 2.02 to 6.74) compared to placebo (Corona et al., J Sex Med 2023). Intramuscular depot preparations including testosterone cypionate carry higher erythrocytosis rates than transdermal formulations because of greater peak serum concentrations.

Monitoring and Management Thresholds

The Endocrine Society recommends measuring hematocrit at baseline, 3 months, and 12 months, then annually. If hematocrit exceeds 54%, therapy should be held, the patient evaluated for hypoxia or sleep apnea driving the erythrocytosis, and the dose reduced or the delivery route changed on resumption (Bhasin et al., J Clin Endocrinol Metab 2018). Therapeutic phlebotomy is sometimes used short-term. Switching from cypionate to a daily transdermal preparation flattens the serum testosterone peak and may reduce erythrocytosis risk in vulnerable patients.

Other Potential Oncologic Signals

Hepatocellular Considerations

Injectable testosterone cypionate is a parenterally administered ester; it avoids first-pass hepatic metabolism. The hepatocellular carcinoma risk associated with oral 17-alpha-alkylated androgens does not apply to testosterone cypionate (Shahidi, Clin J Gastroenterol 2009). Peliosis hepatis and hepatic adenoma, documented with oral androgens, have not been reported in controlled trials of parenteral testosterone at replacement doses.

Bladder and Colorectal Signals

No randomized trial has identified a statistically significant increase in bladder or colorectal cancer incidence attributable to testosterone therapy. Epidemiologic data are conflicting; some observational studies report inverse associations between testosterone levels and colorectal cancer risk, though confounding by BMI, metabolic syndrome, and surveillance intensity makes causal interpretation unreliable.

Lymphoma and Hematologic Malignancy

Testosterone's stimulation of erythropoiesis raises the question of broader hematologic effects. No clinical trial evidence links testosterone cypionate to lymphoma or leukemia at replacement doses. The 2023 TRAVERSE safety analysis did not identify excess hematologic malignancy in the testosterone arm (Lincoff et al., NEJM 2023).

Contraindications, Pre-Treatment Screening, and Monitoring Protocol

A structured screening and monitoring approach reduces the probability of harm in men prescribed testosterone cypionate. The framework below reflects the Endocrine Society 2018 guideline, the AUA 2022 testosterone deficiency guideline, and TRAVERSE safety data.

Pre-Treatment Evaluation

Before initiating testosterone cypionate, clinicians should confirm:

• Total testosterone below 300 ng/dL on two separate morning blood draws (Bhasin et al., J Clin Endocrinol Metab 2018)
• PSA below 4.0 ng/mL (or urology consultation if 2.5 to 4.0 ng/mL with risk factors)
• No palpable prostate nodule or asymmetry on DRE
• Hematocrit below 50% at baseline
• No active or suspected prostate or breast cancer
• No untreated severe obstructive sleep apnea (which exacerbates erythrocytosis risk)
• No class III or IV heart failure

The FDA-approved prescribing label (FDA, testosterone cypionate injection, 2018) lists breast or prostate cancer as absolute contraindications, with the label warning that androgens may stimulate growth of occult prostate carcinoma.

On-Therapy Monitoring Schedule

At 3 months: serum testosterone (trough for cypionate, drawn just before the next injection), PSA, hematocrit, blood pressure, and symptom review.

At 12 months: repeat all 3-month labs plus DRE, lipid panel, and bone density if baseline osteoporosis was present.

After 12 months: annual monitoring as above if the patient is stable and asymptomatic.

Any PSA rise exceeding 1.4 ng/mL within 12 months of starting therapy triggers urology referral, per Endocrine Society guidance. PSA doubling time below 12 months at any point on therapy is a separate indication for urologic evaluation.

Dose and Formulation Considerations

Standard hypogonadism dosing of testosterone cypionate is 100 to 200 mg intramuscularly every 1 to 2 weeks, targeting a mid-normal trough of 400 to 500 ng/dL. Weekly dosing at half the biweekly dose (50 to 100 mg per week) reduces peak-to-trough fluctuation. Lower peak concentrations correlate with lower erythrocytosis incidence (Ramasamy et al., BJU Int 2014). Subcutaneous injection of testosterone cypionate is used off-label at lower volumes and produces flatter pharmacokinetics, though this route lacks FDA approval.

What Clinicians and Guidelines Say

The Endocrine Society 2018 guideline states: "We recommend against testosterone therapy in men who are actively trying to conceive, or who have breast or prostate cancer, a palpable prostate nodule or induration on DRE, PSA >4 ng/mL, or PSA >3 ng/mL with a high risk of prostate cancer without further urological evaluation." (Bhasin et al., J Clin Endocrinol Metab 2018)

The TRAVERSE investigators concluded in their 2023 NEJM report: "Testosterone-replacement therapy was noninferior to placebo with respect to the incidence of major adverse cardiac events... The rates of prostate cancer were similar in the two groups." (Lincoff et al., NEJM 2023)

These two statements together define the current clinical consensus: testosterone cypionate does not appear to initiate prostate cancer in hypogonadal men, but it remains absolutely contraindicated when cancer is known or suspected, and PSA surveillance is non-negotiable on therapy.

Special Populations

Men Over 65

The T-Trials enrolled men 65 and older exclusively. The PSA signal (mean rise 0.30 ng/mL) is relevant because baseline prostate cancer prevalence is higher in this age group. In the T-Trials, 5.5% of testosterone-treated men required prostate biopsy versus 3.3% of placebo-treated men, driven by PSA thresholds rather than confirmed cancer diagnoses (Snyder et al., NEJM 2016). The number needed to trigger one additional biopsy was approximately 45 men treated for 12 months.

Men With Metabolic Syndrome or Obesity

Obesity increases aromatase activity in adipose tissue, producing higher baseline estradiol and potentially higher estradiol on TRT. No trial has shown that obesity independently predicts breast or prostate cancer risk from TRT, but higher estradiol levels may worsen gynecomastia and warrant monitoring of serum estradiol alongside testosterone.

Transgender Women Discontinuing Testosterone

This is outside the male hypogonadism indication for testosterone cypionate but deserves clinical mention. Transgender men (assigned female at birth) who have received long-term testosterone therapy retain ovarian and uterine tissue unless surgically removed. Testosterone does not provide endometrial or ovarian cancer protection; gynecologic surveillance should continue per standard intervals (ACOG Practice Bulletin).